Develop business strategies Of Polycythemia Vera - Pipeline Review, H1 2018
"The Report Polycythemia
Vera - Pipeline Review, H1 2018 provides information on pricing,
market analysis, shares, forecast, and company profiles for key
industry participants. - MarketResearchReports.biz"
About
Polycythemia
Vera
Market
Global Markets Direct's latest
Pharmaceutical and Healthcare disease pipeline guide Polycythemia
Vera - Pipeline Review, H1 2018, provides an overview of the
Polycythemia Vera (Oncology) pipeline landscape.
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1581041
Polycythemia Vera (PV) is a stem
cell disorder characterized as a panhyperplastic, malignant and
neoplastic marrow disorder. Symptoms include itchiness, headache,
dizziness, weakness and excessive sweating. The risk of polycythemia
vera increases with age. Treatment includes alkylating agents.
Report Highlights
Global Markets Direct's
Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera
- Pipeline Review, H1 2018, provides comprehensive information on the
therapeutics under development for Polycythemia Vera (Oncology),
complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and
latest news and press releases.
Request
for TOC @
https://www.marketresearchreports.biz/reports/1581041/polycythemia-vera-pipeline-review-h1-2018-market-research-reports/toc
The
Polycythemia Vera (Oncology) pipeline guide also reviews of key
players involved in therapeutic development for Polycythemia Vera and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in
Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages
are 1, 1, 5, 3 and 2 respectively.
Polycythemia Vera (Oncology)
pipeline guide helps in identifying and tracking emerging players in
the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage. The guide is built using data and information
sourced from Global Markets Directs proprietary databases,
company/university websites, clinical trial registries, conferences,
SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most
recent developments are captured on a real time basis.
Note: Certain content / sections
in the pipeline guide may be removed or altered based on the
availability and relevance of data.
Scope
- The pipeline guide provides a
snapshot of the global therapeutic landscape of Polycythemia Vera
(Oncology).
- The pipeline guide reviews
pipeline therapeutics for Polycythemia Vera (Oncology) by companies
and universities/research institutes based on information derived
from company and industry-specific sources.
- The pipeline guide covers
pipeline products based on several stages of development ranging from
pre-registration till discovery and undisclosed stages.
- The pipeline guide features
descriptive drug profiles for the pipeline products which comprise,
product description, descriptive licensing and collaboration details,
R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key
companies involved in Polycythemia Vera (Oncology) therapeutics and
enlists all their major and minor projects.
- The pipeline guide evaluates
Polycythemia Vera (Oncology) therapeutics based on mechanism of
action (MoA), drug target, route of administration (RoA) and molecule
type.
- The pipeline guide encapsulates
all the dormant and discontinued pipeline projects.
- The pipeline guide reviews
latest news related to pipeline therapeutics for Polycythemia Vera
(Oncology)
View
Report @
https://www.marketresearchreports.biz/reports/1581041/polycythemia-vera-pipeline-review-h1-2018-market-research-reports
Reasons to buy
- Procure strategically important
competitor information, analysis, and insights to formulate effective
R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
- Find and recognize significant
and varied types of therapeutics under development for Polycythemia
Vera (Oncology).
- Classify potential new clients
or partners in the target demographic.
- Develop tactical initiatives by
understanding the focus areas of leading companies.
- Plan mergers and acquisitions
meritoriously by identifying key players and its most promising
pipeline therapeutics.
- Formulate corrective measures
for pipeline projects by understanding Polycythemia Vera (Oncology)
pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing
and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential
and scope.
- Adjust the therapeutic portfolio
by recognizing discontinued projects and understand from the know-how
what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report
Coverage
Polycythemia Vera - Overview
Polycythemia Vera - Therapeutics
Development
Pipeline Overview
Pipeline by Companies
Products under Development by
Companies
Polycythemia Vera - Therapeutics
Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of
Administration
Assessment by Molecule Type
Polycythemia Vera - Companies
Involved in Therapeutics Development
AbbVie Inc
Bristol-Myers Squibb Co
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Italfarmaco SpA
Nerviano Medical Sciences Srl
PharmaEssentia Corp
SELLAS Life Sciences Group Inc
Polycythemia Vera - Drug Profiles
anagrelide hydrochloride CR - Drug
Profile
Product Description
Mechanism Of Action
R&D Progress
dasatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fedratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idasanutlin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idelalisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peginterferon alfa-2a - Drug
Profile
Product Description
Mechanism Of Action
R&D Progress
ropeginterferon alfa-2b - Drug
Profile
Product Description
Mechanism Of Action
R&D Progress
veliparib ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycythemia Vera - Dormant
Projects
Polycythemia Vera - Discontinued
Products
Polycythemia Vera - Product
Development Milestones
Featured News & Press Releases
Dec
11, 2017: Impact Biomedicines Presents Analysis at the 2017 ASH
Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke
Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials
Dec 11, 2017: Italfarmaco Presents
Positive Phase II Study Results for Givinostat in Polycythemia Vera
Patients at the ASH Annual Meeting
Dec 10, 2017: PharmaEssentia
Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in
Polycythemia Vera at the American Society of Hematology (ASH) Annual
Meeting 2017
Dec 05, 2017: Italfarmaco
Announces Givinostat Clinical Trial Presentations at the 59th
American Society of Hematology (ASH) Annual Meeting
Nov 27, 2017: Impact Biomedicines
to Present Retrospective Data on Fedratinib at the 2017 ASH Annual
Meeting
Jun 25, 2017: AOP Orphan and
PharmaEssentia announce latest clinical results for Ropeginterferon
alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd
Congress of the European Hematology Association (EHA) in Madrid
Mar 14, 2017: AOP Orphan
Pharmaceuticals announces start of EMA marketing authorization
application procedure for Ropeginterferon alfa-2b in Polycythemia
Vera
Dec 05, 2016: AOP Orphan and
PharmaEssentia Announce Pivotal Phase III results for Ropeginterferon
alfa-2b in Polycythemia Vera at the American Society of Hematology
(ASH) Annual Meeting 2016
Nov 28, 2016: PharmaEssentia
Announces Phase III PROUD-PV Study Results to be Presented at ASH
Annual Meeting Oral Presentation
Sep 12, 2016: Galena Biopharma
Expands GALE-401 Intellectual Property Protection with Patent
Issuance in Japan
May 09, 2016: Merganser Biotech
Announces Issuance of U.S. Patent 9,315,545 Covering Development
Compound M012
May 06, 2016: Drug-like Compound
Shows Promise in Treating Two Blood Diseases
Dec 08, 2015: Galena Biopharma
Presents Final GALE-401 Phase 2 Clinical Data at the 57th American
Society of Hematology (ASH) Annual Meeting and Exposition
Nov 06, 2015: Galena Biopharma to
Present Final GALE-401 Phase 2 Clinical Data at the 57th American
Society of Hematology Annual Meeting and Exposition
Mar 05, 2015: AOP Orphan
Pharmaceuticals announces progress of pivotal phase III trial
PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting,
mono-pegylated Interferon for treatment of Polycythemia Vera
About us
MarketResearchReports.biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Comments
Post a Comment